Almost ten months into his presidency, Joe Biden has announced his pick to lead the US Food and Drug Administration (FDA). If confirmed by the Senate, the nominee, Dr Robert Califf, would become commissioner for a second time after leading…
David H. Crean summarizes the recent 40th annual J.P. Morgan Healthcare Conference 2022 that was held in a virtual format. Crean underlines the importance of the Conference for establishing the tone…
The oncology field has exploded in the past 20 years and pharma companies now have a wide range of approaches available to them as they look to identify, treat, and…
PharmaBoardroom has spoken to leaders from several important global patient advocacy organisations in 2021 who shared their concerns on crucial global healthcare issues. These range from the greater levels of…
Claire Saxton and Lauren Kriegel of Cancer Support Community, the largest professionally led non-profit network of cancer support worldwide, discuss how cancer patient and caregiver perspectives need to be better…
Paediatric oncologist Navin Pinto, MD outlines the current use and potential of CAR-T therapies in his field, including the manufacturing challenges that still need to be addressed. Dr Pinto also…
Melanie Croce-Galis, RN, MPH explains the specificities of her work as patient engagement lead for Novartis Oncology in the US market, where significant disparities in patient access to information and…
David H. Crean, Managing General Partner for Coast BioVentures, updates and highlights the latest trends in the cell and gene therapy market for deal activities and financings over the past…
The National Organization for Rare Disorders (NORD) is set to host its annual Rare Diseases and Orphan Products Breakthrough Summit on October 18-19th. Ahead of the Summit, the Chair of…
Susan L. Lang outlines how pharma companies can navigate drug formulary exclusions, numbers of which have been rising in recent years, and ensure that newly FDA approved medicines can make…
PhRMA’s Lori Reilly warns that, as US policymakers seek to reduce drug prices, they must avoid policies that reduce access and choice. America is the centre of cutting-edge biopharmaceutical…
Bernie Zeiher, chief medical officer (CMO) of Astellas explains why the ‘patient-defined value’ of medicines is crucial to developing therapies that truly address patients’ unmet medical needs. Zeiher outlines some…
Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, highlights the achievements of the company’s Rare Humanitarian Program over the last 30 years, bringing treatments to patients in developing…
See our Cookie Privacy Policy Here